New Orleans riverfront streetcarThe 2016 annual meeting of the American Association for Cancer Research (AACR) takes place next month in New Orleans. (Twitter #AACR16).

While many people have focused on the presentation of clinical data at ASCO, we have long argued that emerging scientific data at AACR actually give early hint of what’s to come down the pipeline.

Anticipating these trends and spotting promising new compounds or combinations is probably more art than science, but nonetheless is a very useful and important exercise.

AACR is the most important meeting of the year for cancer new product development! 

Tomorrow, we will be reviewing the actual abstracts, posters, late breakers and what they entail, including important new data such as BMS’s CheckMate–141 exploring nivolumab in Head & Neck cancer as well as the combination of nivolumab plus ipilimumab in CheckMate–069 for advanced melanoma.

In the meantime, what are the main hot topics emerging from this year’s meeting in targeted therapies and immunotherapies?  What do the key scientific sessions tell us about new directions that lie ahead?

To learn more, subscribers can sign-in below or you sign-up in the blue box.

Posted by 

Purchase Access to Premium Content

PLEASE READ BEFORE YOU BUY. Click on blue icon to purchase a PERSONAL, INDIVIDUAL license to premium content. Please READ our TERMS OF USE before purchasing (link at bottom of page): You are NOT PERMITTED to share access or copies of posts. If you work for a CONSULTING FIRM, AGENCY, or are in PR or COMMUNICATIONS you cannot purchase an INDIVIDUAL license through this site without prior approval (even if your use is personal) and typically a CORPORATE license will be required. Please CONTACT US to discuss how you might use our content & obtain a quote for the appropriate license. Rates may change without notice and are non-refundable. If you in any doubt about whether you can buy through the blue icon, PLEASE CONTACT US first.